Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas…
News
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas…
EvolveImmune Therapeutics Enters into Strategic Research Collaboration with Kennedy Institute of Rheumatology
Collaboration with Researchers at University of Oxford to Utilize State-of-the-Art Technology to Characterize Immune Synapse…
EvolveImmune Therapeutics Enters into Strategic Research Collaboration with Kennedy Institute of Rheumatology
Collaboration with Researchers at University of Oxford to Utilize State-of-the-Art Technology to Characterize Immune Synapse…
Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor
Topline data from the Phase 1 SAD/MAD trial of VTX3232 are expected in H1 2024…
Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor
Topline data from the Phase 1 SAD/MAD trial of VTX3232 are expected in H1 2024…
Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications
Initiation of NX-2127 Phase 1b expansion cohort in patients with diffuse large B cell lymphoma…
Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications
Initiation of NX-2127 Phase 1b expansion cohort in patients with diffuse large B cell lymphoma…
Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
AUSTIN, Texas, June 14, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a…
Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
AUSTIN, Texas, June 14, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a…
Tilray Brands Expands Beer Portfolio and Launches Good Supply Light Beer
Tilray Introduces New Easy-Drinking Light Beer Brand, Good Supply, in the U.S. Good Supply Easy…
Tilray Brands Expands Beer Portfolio and Launches Good Supply Light Beer
Tilray Introduces New Easy-Drinking Light Beer Brand, Good Supply, in the U.S. Good Supply Easy…
Jaden Smith to Speak at World’s Largest Psychedelic Science Conference
Multi-hyphenate entertainer, entrepreneur, advocate, and musician to speak about psychedelic medicine, healing, and mental health…
Jaden Smith to Speak at World’s Largest Psychedelic Science Conference
Multi-hyphenate entertainer, entrepreneur, advocate, and musician to speak about psychedelic medicine, healing, and mental health…
Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference
WILMETTE, Ill., June 14, 2023 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage…
Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference
WILMETTE, Ill., June 14, 2023 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage…
Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage…
Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage…
Eagle Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) and Fast-Track Designation for CAL02, Providing Five-Year Exclusivity Extension
With QIDP, Eagle expects to receive eight or ten years of regulatory exclusivity upon NDA…
Eagle Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) and Fast-Track Designation for CAL02, Providing Five-Year Exclusivity Extension
With QIDP, Eagle expects to receive eight or ten years of regulatory exclusivity upon NDA…